CaliciX™ Max is a high-strength systemic antiviral capsule formulated for cats suffering from severe, refractory, or high-viral-load feline calicivirus (FCV) infections, where standard-dose therapy of 15mg is insufficient.
Each capsule contains: 30 mg of pure EIDD-1931 antiviral, the active antiviral metabolite of molnupiravir, designed for systemic viral suppression in advanced disease states.
This formulation is intended for use under veterinary supervision in cats requiring higher antiviral exposure due to disease severity, body weight, or poor response to conventional therapy.
CaliciX™ Max is designed to support treatment of severe FCV-associated diseases, including:
Severe Oral & Oropharyngeal Disease.
- Severe Feline Chronic Gingivostomatitis (FCGS)
- Caudal Stomatitis with extensive caudal oral inflammation
- Ulcerative Stomatitis unresponsive to dental extractions
- Deep Lingual Ulceration (Viral Glossitis)
- Multifocal Buccal, Labial, and Palatal Ulcers
These conditions are characterized by:
- Extreme oral pain
- Profuse drooling (ptyalism)
- Difficulty eating or swallowing (dysphagia)
- Weight loss and cachexia
- Persistent halitosis and oral bleeding
Systemic & Virulent FCV Disease
CaliciX™ Max may be considered in cases with evidence of high systemic viral burden, including:
Virulent Systemic Feline Calicivirus (VS-FCV)
FCV-associated fever and severe lethargy
Facial or limb edema
Lameness
Pulmonary involvement or pneumonia
Hepatic or pancreatic enzyme elevation
Severe inflammatory response with rapid clinical decline
Refractory or Relapsing Disease
Cats with persistent FCV shedding
Post-extraction FCGS with incomplete response
Chronic stomatitis with repeated relapse after steroids or immunosuppressive therapy
Large or obese cats requiring higher per-dose antiviral exposure
Why High-Strength CaliciX?
CaliciX's EIDD-1931 is the active antiviral form of molnupiravir and demonstrates:
Substantially higher intrinsic antiviral potency than its prodrug
Predictable systemic exposure without reliance on metabolic conversion
Broad activity against RNA viruses, including calicivirus
In severe FCV disease, higher systemic concentrations may be required to:
Rapidly reduce viral replication
Suppress ongoing mucosal and systemic viral injury
Support recovery in cats with advanced inflammation and pain
The 30 mg strength allows veterinarians to achieve these targets with fewer capsules per dose, improving accuracy, compliance, and treatment feasibility.
Designed for Severe Cases & Larger Cats
CaliciX™ Max is particularly suited for:
Cats weighing ≥5 kg with severe disease
Patients requiring greater than 6 mg/kg BID dosing
Situations where multiple 15mg capsules would otherwise be required
This strength supports step-up antiviral therapy while maintaining precise dosing control.
Precision Antiviral Therapy, When It matters most. CaliciX™ Max represents the highest-potency option in the CaliciX™ antiviral line, offering veterinarians a systemic antiviral tool for the most challenging calicivirus cases.When standard dosing is no longer enough, CaliciX™ Max provides a controlled, high-strength antiviral option designed to support stabilization, recovery, and improved quality of life in cats with severe FCV disease.
